Alector (NASDAQ:ALEC) Stock Rating Raised to “Buy” at Wall Street Zen

Posted by Brian Himes on Nov 8th, 2026

Wall Street Zen upgraded shares of Alector (NASDAQ:ALEC – Free Report) from a hold rating to a buy rating in a research note released on Saturday morning,Wall Street Zen reports.

Other equities research analysts have also recently issued research reports about the stock. Morgan Stanley increased their price target on shares of Alector from $2.00 to $3.00 and gave the company an “underweight” rating in a research report on Tuesday, October 6th. Weiss Ratings raised shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. HC Wainwright upped their price objective on shares of Alector from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Finally, UBS Group reiterated a “neutral” rating and set a $1.50 target price on shares of Alector in a report on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $4.62.

Get Our Latest Stock Analysis on Alector

Alector Stock Up 9.6%

Shares of Alector stock opened at $2.29 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.26 and a current ratio of 5.26. Alector has a 52-week low of $1.09 and a 52-week high of $2.76. The stock has a market capitalization of $255.70 million, a price-to-earnings ratio of 6.54 and a beta of 0.61. The company’s 50 day moving average price is $2.06 and its 200-day moving average price is $2.03.

Alector (NASDAQ:ALEC – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of ($0.23) by $1.34. Alector had a net margin of 23.87% and a return on equity of 399.98%. The company had revenue of $162.87 million for the quarter, compared to the consensus estimate of $2.19 million. Equities research analysts forecast that Alector will post -0.55 EPS for the current year.

Insiders Place Their Bets

In other Alector news, CFO Neil Berkley sold 29,251 shares of the company’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total value of $77,807.66. Following the completion of the transaction, the chief financial officer directly owned 350,649 shares in the company, valued at approximately $932,726.34. This represents a 7.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Arnon Rosenthal sold 72,606 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total transaction of $193,131.96. Following the completion of the sale, the chief executive officer directly owned 2,294,600 shares of the company’s stock, valued at approximately $6,103,636. This represents a 3.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 111,303 shares of company stock worth $295,633. Insiders own 8.30% of the company’s stock.

Institutional Trading of Alector

Several institutional investors and hedge funds have recently bought and sold shares of ALEC. BlackRock Inc. purchased a new position in shares of Alector during the 2nd quarter worth approximately $15,774,000. Nantahala Capital Management LLC bought a new position in Alector in the 2nd quarter worth about $8,679,399. Merck & Co. Inc. bought a new position in Alector in the 2nd quarter worth about $7,126,896. ADAR1 Capital Management LLC purchased a new stake in Alector during the 2nd quarter valued at about $5,796,000. Finally, Spruce Street Capital LP grew its position in Alector by 87.9% during the 1st quarter. Spruce Street Capital LP now owns 2,101,068 shares of the company’s stock valued at $4,517,000 after purchasing an additional 983,082 shares during the last quarter. 85.83% of the stock is currently owned by hedge funds and other institutional investors.

Alector Company Profile

(Get Free Report)

Alector, Inc (NASDAQ: ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research platform, known as immuno-neurology, is designed to use the body’s immune system to protect or restore the brain’s ability to maintain healthy neural connections.

Alector’s investigational pipeline has included antibody-based treatments for conditions such as frontotemporal dementia and Alzheimer’s disease. Its programs have targeted biological pathways associated with neurodegeneration, including progranulin and TREM2.